- Drugs (psychoactive) - World Health Organization (WHO)
The use of psychoactive drugs without medical supervision is associated with significant health risks and can lead to the development of drug use disorders Drug use disorders, particularly when untreated, increase morbidity and mortality risks for individuals, can trigger substantial suffering and lead to impairment in personal, family, social, educational, occupational or other important
- WHO Drug Information
About WHO Drug Information WHO Drug Information is a quarterly journal providing an overview of topics relating to medicines development and regulation which is targeted to a wide audience of health professionals and policy makers Launched in 1987, WHO Drug Information communicates the latest international news and trends to regulatory agencies, academic and training institutions, researchers
- Alcohol, Drugs and Addictive Behaviours
The Unit works globally to improve health and well-being of populations by articulating, promoting, supporting and monitoring evidence-informed policies, strategies and interventions to reduce the burden associated with alcohol, drugs and addictive behaviours
- Anatomical Therapeutic Chemical (ATC) Classification
In the Anatomical Therapeutic Chemical (ATC) classification system, the active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties Drugs are classified in groups at five different levels
- Obesity: GLP-1 therapies
GLP-1 therapies (glucagon-like peptide-1 receptor agonists) are a class of medications that mimic the natural GLP-1 hormone, which helps regulate blood sugar and appetite They were originally used for managing type 2 diabetes, but are now also approved for treating obesity and weight loss Some GLP-1 drugs lower the risk of heart attack, stroke, and heart failure, and reduce the incidence of
- WHO warns of widespread resistance to common antibiotics worldwide
One in six laboratory-confirmed bacterial infections causing common infections in people worldwide in 2023 were resistant to antibiotic treatments, according to a new World Health Organization (WHO) report launched today
- WHO announces landmark changes in treatment of drug-resistant tuberculosis
The World Health Organization (WHO) today released its Consolidated guidelines on tuberculosis (TB)- Module 4: treatment and care, consolidating all previous guidelines into a single comprehensive document and introducing significant improvements in treatment options for people with multidrug-resistant or rifampicin-resistant tuberculosis (MDR RR-TB)
- WHO launches new framework to tackle drug resistance to HIV, hepatitis . . .
WHO has released the Integrated drug resistance action framework for HIV, hepatitis B and C and sexually transmitted infections, 2026–2030, a landmark roadmap to address the growing threat of drug resistance and safeguard progress toward ending AIDS and the epidemics of hepatitis B, hepatitis C and sexually transmitted infections (STIs) as public health concerns
|